Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Tarsus Pharmaceuticals's pretax income for the
three
months ended in Jun. 2026 was $-15.8 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-39.3 Mil.
Tarsus Pharmaceuticals's pretax margin was -9.11%.
During the past 8 years, Tarsus Pharmaceuticals's highest Pretax Margin was -6.49%. The lowest was -778.89%. And the median was -63.16%.
During the past 8 years, Tarsus Pharmaceuticals's highest Pretax Margin was -6.49%. The lowest was -778.89%. And the median was -63.16%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Pre-Tax Income Related Terms
Tarsus Pharmaceuticals Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Tarsus Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TARS vs VERA, BEAM, KOD: Pre-Tax Income Comparison
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Pre-Tax Income of $-39.3 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Pre-Tax Income too high?
Tarsus Pharmaceuticals' current Pre-Tax Income is $-39.3 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Pre-Tax Income compare to VERA and BEAM?
Tarsus Pharmaceuticals' Pre-Tax Income of $-39.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Pre-Tax Income is $-39.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $157.42, compared to a current price of $72.73 — trading 53.8% below its estimated fair value. The current Pre-Tax Income is $-39.3 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Pre-Tax Income is $-39.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $72.73 is trading 53.8% below its estimated GF Value™ of $157.42.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
Pre-Tax Income: $-39.3 Mil
GF Value™: $157.42 vs. price of $72.73 (53.8% below fair value)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
43GF Score
Get the complete analysis for TARS
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
